The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy t
Pfizer's close-fought contest with GSK to bring a next-generation meningitis vaccine to market has entered the final rounds, with the former ahead on points following the readout of a pivot
Pfizer and BioNTech's COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA's human medicines committee, shortly after the panel gave its blessi
On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer's vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent inva
The NHS is moving to the next phase of its SARS-CoV-2 vaccination programme, following health secretary Steve Barclay’s acceptance of advice from the Joint Committee on Vaccination and Immu
The EMA's human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that include sequences coding for Omicron spike protein as